Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.
Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.
Filter by Form Type:
Industry:Biotechnologyβ
2026-07-16CYBN6-KHelus Pharma Closes US$50 Million Underwritten Offering to Fund Phase 3 MDD ProgramHIGH
On June 25, 2026, Helus Pharma (the commercial operating name of Cybin Inc.) closed an underwritten public offering of 10,309,280 common shares at a price of US$4.85 per share. The offering generated approximately US$50 million in aggregate gross proceeds. Cantor Fitzgerald & Co. and Barclays Capital Inc. served as joi...
BiotechnologyEquity Offering